Given his training in developmental biology,
Raman focused the team to seek a novel drug target on genes important to the development of model organisms — fruit flies (Drosophila) and yeast (Saccharomyces cerevisiae)-- rather than on oncogenes that transform a normal cell into a cancer cell.